Low-Dose Interleukin-2 Ameliorates Colitis in a Preclinical Humanized Mouse Model
Jeremy A. Goettel(Vanderbilt University Medical Center), Scott B. Snapper(Massachusetts General Hospital), James B. Canavan(King's College London), Joshua R. Friedman(Spark Therapeutics (United States)), Kaiyue Peng(Children's Hospital of Fudan University), Sarah Wall(Boston Children's Hospital), Vanessa Mitsialis(Brigham and Women's Hospital), Jordan Gringauz(Boston Children's Hospital), Daniel Kotlarz(LMU Klinikum), Michael Field(Hunter Genetics), Liza Konnikova(Yale University), Rohini Emani(Boston Children's Hospital), Amy M. Tsou(Oral Roberts University), Aisling O’Hara Hall(Janssen (United States)), Matthew Kowalik(Boston Children's Hospital), Jennifer E. Towne(Amgen (United States)), Alexandra Griffith(Brigham and Women's Hospital), Scott E. Plevy(Protagonist Therapeutics (United States)), Ying Huang(Children's Hospital of Fudan University), Sandra M. Frei(Boston Children's Hospital), David W. Illig(Boston Children's Hospital)
Cited by 35
Related Papers
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k